Chaperones in Neurodegeneration
- PMID: 26468185
- PMCID: PMC4604223
- DOI: 10.1523/JNEUROSCI.2600-15.2015
Chaperones in Neurodegeneration
Abstract
Cellular protein homeostasis (proteostasis) maintains the integrity of the proteome and includes protein synthesis, folding, oligomerization, and turnover; chaperone proteins assist with all of these processes. Neurons appear to be especially susceptible to failures in proteostasis, and this is now increasingly recognized as a major origin of neurodegenerative disease. This review, based on a mini-symposium presented at the 2015 Society for Neuroscience meeting, describes new work in the area of neuronal proteostasis, with a specific focus on the roles and therapeutic uses of protein chaperones. We first present a brief review of protein misfolding and aggregation in neurodegenerative disease. We then discuss different aspects of chaperone control of neuronal proteostasis on topics ranging from chaperone engineering, to chaperone-mediated blockade of protein oligomerization and cytotoxicity, to the potential rescue of neurodegenerative processes using modified chaperone proteins.
Significance statement: Aberrant protein homeostasis within neurons results in protein misfolding and aggregation. In this review, we discuss specific roles for protein chaperones in the oligomerization, assembly, and disaggregation of proteins known to be abnormally folded in neurodegenerative disease. Collectively, our goal is to identify therapeutic mechanisms to reduce the cellular toxicity of abnormal aggregates.
Keywords: Parkinson's disease; chaperone; heat shock proteins; neurodegeneration; protein misfolding; proteostasis.
Copyright © 2015 the authors 0270-6474/15/3513853-07$15.00/0.
References
-
- Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9:293–348. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DA005084/DA/NIDA NIH HHS/United States
- DK102635/DK/NIDDK NIH HHS/United States
- R01 MH103848/MH/NIMH NIH HHS/United States
- GM099836/GM/NIGMS NIH HHS/United States
- NS073899/NS/NINDS NIH HHS/United States
- NS073740/NS/NINDS NIH HHS/United States
- AG045741/AG/NIA NIH HHS/United States
- R01 NS092829/NS/NINDS NIH HHS/United States
- R01 NS073899/NS/NINDS NIH HHS/United States
- DA05084/DA/NIDA NIH HHS/United States
- DP2 OD002177/OD/NIH HHS/United States
- DP2OD002177/OD/NIH HHS/United States
- R01 NS073740/NS/NINDS NIH HHS/United States
- MH103848/MH/NIMH NIH HHS/United States
- R01 GM099836/GM/NIGMS NIH HHS/United States
- NS092829/NS/NINDS NIH HHS/United States
- R21 AG045741/AG/NIA NIH HHS/United States
- R21 NS067354/NS/NINDS NIH HHS/United States
- R01 DK102635/DK/NIDDK NIH HHS/United States
- R56 DA005084/DA/NIDA NIH HHS/United States
- NS067354/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases